To date, many FLT3 inhibitors have been evaluated in clinical trials, yet gilteritinib is the only drug that has been successfully approved worldwide as a monotherapy for the treatment of AML patients harboring FLT3 mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.